• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钙离子通道阻滞剂在家庭医疗中的应用。

Use of calcium ion entry blockers in family practice.

出版信息

Can Fam Physician. 1983 Feb;29:285-8.

PMID:21283319
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2153756/
Abstract

Verapamil, nifedipine, and diltiazem are drugs which decrease intracellular calcium in cardiac muscle, smooth muscle, and nodal cardiac cells. Unlike B-blockers, each drug acts at a different site on the cell membrane and has an important difference in overall action. Verapamil is used to treat angina, systemic hypertension, hypertrophic cardiomyopathy, and supraventricular and junctional tachyarrhythmias. Nifedipine is useful in angina, vasospastic disorders, and hypertension. A specific role for diltiazem is now being defined.

摘要

维拉帕米、硝苯地平、地尔硫卓是降低心肌、平滑肌和心脏结细胞细胞内钙的药物。与β受体阻滞剂不同,每种药物在细胞膜的不同部位起作用,其总体作用有重要差异。维拉帕米用于治疗心绞痛、全身性高血压、肥厚型心肌病和室上性及结性心动过速。硝苯地平对心绞痛、血管痉挛性疾病和高血压有效。地尔硫卓的具体作用正在确定中。

相似文献

1
Use of calcium ion entry blockers in family practice.钙离子通道阻滞剂在家庭医疗中的应用。
Can Fam Physician. 1983 Feb;29:285-8.
2
Gene expression profiling of calcium-channel antagonists in the heart of hypertensive and normotensive rats reveals class specific effects.高血压和正常血压大鼠心脏中钙通道拮抗剂的基因表达谱揭示了类别特异性效应。
Vascul Pharmacol. 2016 Dec;87:121-128. doi: 10.1016/j.vph.2016.09.001. Epub 2016 Sep 6.
3
Calcium ions, drug action and the heart--with special reference to calcium antagonist drugs.钙离子、药物作用与心脏——特别提及钙拮抗剂药物
Pharmacol Ther. 1984;25(3):271-95. doi: 10.1016/0163-7258(84)90002-0.
4
Excitation-contraction coupling in cardiac and vascular smooth muscle: modification by calcium-entry blockade.心脏和血管平滑肌中的兴奋-收缩偶联:钙内流阻滞剂的影响
Circulation. 1987 Jun;75(6 Pt 2):V3-14.
5
Update on calcium-channel blocking agents.钙通道阻滞剂的最新进展。
Clin Pharm. 1983 Sep-Oct;2(5):403-16.
6
Calcium-channel blocking agents.钙通道阻滞剂
Clin Pharm. 1982 Jan-Feb;1(1):17-33.
7
Nifedipine, diltiazem, bepridil and verapamil uptakes into cardiac and smooth muscles.硝苯地平、地尔硫䓬、苄普地尔和维拉帕米在心肌和平滑肌中的摄取。
Eur J Pharmacol. 1983 Feb 18;87(2-3):199-207. doi: 10.1016/0014-2999(83)90330-8.
8
Differential effects of nifedipine, verapamil, and diltiazem on noradrenaline-induced contractions, adrenergic transmitter release, and alpha-adrenoceptor binding in the female rabbit urethra.硝苯地平、维拉帕米和地尔硫䓬对雌性兔尿道中去甲肾上腺素诱导的收缩、肾上腺素能递质释放及α-肾上腺素能受体结合的不同作用。
Naunyn Schmiedebergs Arch Pharmacol. 1984 May;326(1):14-21. doi: 10.1007/BF00518773.
9
Calcium antagonists. Clinical use in the treatment of systemic hypertension.钙拮抗剂。在系统性高血压治疗中的临床应用。
Drugs. 1983 Feb;25(2):154-77. doi: 10.2165/00003495-198325020-00004.
10
Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.钙通道拮抗剂。第三部分:在高血压和室上性心律失常中的应用及疗效比较。次要适应症。
Cardiovasc Drugs Ther. 1988 Mar;1(6):625-56. doi: 10.1007/BF02125750.

本文引用的文献

1
Calcium antagonists: an overview.钙拮抗剂:概述
Angiology. 1982 Aug;33(8):489-91. doi: 10.1177/000331978203300801.
2
Symposium on Cardiovascular Disease and Calcium Antagonists. Introduction.心血管疾病与钙拮抗剂研讨会。引言。
Am J Cardiol. 1982 Feb 18;49(3):497-8. doi: 10.1016/s0002-9149(82)80001-5.
3
Pharmacological basis for the therapeutic applications of slow-channel blocking drugs.
Angiology. 1982 Aug;33(8):492-515. doi: 10.1177/000331978203300802.
4
Management of arrhythmias with "calcium antagonists".
Angiology. 1982 Aug;33(8):540-54. doi: 10.1177/000331978203300805.
5
Calcium antagonists in the treatment of individuals with ischemic heart disease.
Angiology. 1982 Aug;33(8):522-39. doi: 10.1177/000331978203300804.
6
The hemodynamic effects of calcium channel blocking agents: a brief review.钙通道阻滞剂的血流动力学效应:简要综述。
Angiology. 1982 Aug;33(8):516-21. doi: 10.1177/000331978203300803.